It's gonna be a few years before this stock does anything substantial...so goes the business of getting the drug into the hands of those who need it most. There are two things to keep in mind, maybe three. 1) Eli Lilly is making its way into China and its market, 2) there are patents expiring on medicines which had brought in plenty of revenue for Eli Lilly, 3) the population (baby boomers) are getting older, Alzheimer's is not really understood, yet Dr. Davies is doing some remarkable stuff which other researchers for other companies haven't been able to do, good things for this emerging market.
